BioPlus Acquisition Corp. Class A Ordinary Shares
BIOS
BIOS was delisted on the 6th of October, 2023.
67 hedge funds and large institutions have $202M invested in BioPlus Acquisition Corp. Class A Ordinary Shares in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
3% more funds holding
Funds holding: 65 → 67 (+2)
5% more capital invested
Capital invested by funds: $193M → $202M (+$8.95M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$6.59M |
| 2 |
ACM
Atalaya Capital Management
New York
|
+$2.5M |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$2.5M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.37M |
| 5 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$2.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$7.07M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$4.03M |
| 3 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$2.5M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$2.06M |
| 5 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$1.44M |
BIOS Hedge Fund Activity: Q3 2022 in Review
67 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) for Q3 2022, worth a combined $202M — up 4.6% from $193M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BIOS positions and 6 closed out — a net gain of 2 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was Highbridge Capital Management, adding an estimated $6.59M. The largest seller was Goldman Sachs, cutting an estimated $7.07M.
- 67 institutional investors held BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) as of Q3 2022, up from 65 in Q2 2022.
- Funds reported $202M of BioPlus Acquisition Corp. Class A Ordinary Shares stock for Q3 2022, up 4.6% quarter-over-quarter.
- 8 funds opened new BioPlus Acquisition Corp. Class A Ordinary Shares positions in Q3 2022 and 6 closed out, a net change of +2 holders.
- The largest BioPlus Acquisition Corp. Class A Ordinary Shares buyer in Q3 2022 was Highbridge Capital Management, an estimated $6.59M added.
- The largest BioPlus Acquisition Corp. Class A Ordinary Shares seller in Q3 2022 was Goldman Sachs, an estimated $7.07M sold.
Based on aggregated 13F filings for Q3 2022.